Sarah Jane Tribble
Sarah Jane Tribble joined Kaiser Health News from Ideastream — the NPR/PBS member station in Cleveland, Ohio — where she covered health, health policy and the business of health care. She won an Emmy as host of the station’s health care programming and was a regular contributor on NPR’s Morning Edition and All Things Considered.
-
The potential for conflict of interest when health policy experts also serve on the boards of pharma companies
By Sarah Jane Tribble, Kaiser Health News
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
Share/ Jun 29, 2018 at 5:24 PM -
Trump’s drug cost cutting plans include transparency, but critics doubt much will change
By Sarah Jane Tribble and Liz Szabo, Kaiser Health News
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.
Share/ May 13, 2018 at 6:00 PM -
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Trump’s view on drug costs: Talk vs. the truth
By Sarah Jane Tribble, Kaiser Health News
President Donald Trump has railed against the high price of prescription drugs, yet many Americans aren’t seeing a change in what they pay out-of-pocket. Here’s a look at the rhetoric thus far versus the results.
Share/ Apr 29, 2018 at 7:00 PM -
How a drugmaker converted the “abortion pill” into a lucrative orphan drug
By Sarah Jane Tribble, Kaiser Health News
The story of Korlym highlights how America’s drug development system can turn an old drug into a new one that treats relatively
few — but often very desperate — patients.Share/ Apr 12, 2018 at 1:47 PM -
Trump’s budget flirts with combating high drug prices
By Sarah Jane Tribble, Kaiser Health News
The White House’s proposal, which comes after Congress passed a two-year spending deal last week, sets the tone for the administration’s focus on prescription drugs.
Share/ Feb 13, 2018 at 8:57 PM -
Experts offered Senate HELP committee 9 proposals to cut drug prices. Here are the odds of passage
By Sarah Jane Tribble, Kaiser Health News
At a hearing held by the Senate Health, Education, Labor and Pensions Committee, experts made nine proposals to lower drug prices. Here’s an analysis on the likelihood of action being taken on each of them.
Share/ Dec 12, 2017 at 7:11 PM -
Drug discount program 340B is at center of debate between CMS, lawmakers and hospitals
By Sarah Jane Tribble, Kaiser Health News
The 340B program requires pharmaceutical companies to give steep discounts to hospitals and clinics that serve high volumes of low-income patients. But a move by CMS to cut Medicare payments for hospitals enrolled in the program has sparked a debate over the program’s future.
Share/ Nov 28, 2017 at 7:28 AM -
CMS is looking for ideas on reducing drug prices for Medicare Part D
By Sarah Jane Tribble, Kaiser Health News
Medicare officials requested comments late Thursday on how to use discounts and rebates to help decrease what enrollees pay for prescriptions.
Share/ Nov 17, 2017 at 7:46 AM -
States investigate pharma companies, CVS Health as diabetes drug prices reach record highs
By Sarah Jane Tribble, Kaiser Health News
The United States is one of the few developed countries without regulations on prescription drug pricing.
Share/ Oct 30, 2017 at 6:44 AM -
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Concerned with abuse of orphan drug program, FDA is rethinking how it approves these medications
By Sarah Jane Tribble, Kaiser Health News
The Food and Drug Administration is changing the way it approves medicines known as “orphan drugs” after revelations that drugmakers may be abusing a law intended to help patients with rare diseases.
Share/ Sep 13, 2017 at 5:47 PM -
Are pharma industry companies converting patients with orphan diseases into lobbyists?
Behind-the-scenes partnerships between the pharmaceutical industry and advocacy groups may work against lowering the cost of high-priced drugs.
Share/ Apr 10, 2017 at 12:35 PM -
Government Accountability Office will investigate potential abuses with Orphan Drug Act
Reports of five- and six-figure annual price tags for orphan drugs have concerned U.S. senators.
Share/ Mar 23, 2017 at 12:21 PM -
High drug price concerns spur request for GAO investigation of Orphan Drug Act
By Sarah Jane Tribble and Sydney Lupkin
Sens. Orrin Hatch (R-Utah), Chuck Grassley (R-Iowa) and Tom Cotton (R-Arkansas.) raised the possibility that regulatory or legislative changes might be needed “to preserve the intent of this vital law” that gives drugmakers lucrative incentives to develop drugs for rare diseases.
Share/ Mar 7, 2017 at 7:08 PM -
5 reasons for the latest drug cost firestorm, this time over Emflaza’s price tag
By Sarah Jane Tribble and Sydney Lupkin
Emflaza, the brand name for deflazacort, has never been approved for sale in the United States, but the steroid has been sold for decades in other countries — at much lower prices
Share/ Feb 16, 2017 at 10:43 AM -
Grassley opens probe into Orphan Drug Act abuses
In a statement, Grassley said the inquiry is “based on reporting from Kaiser Health News” and strong consumer concern about high drug prices.
Share/ Feb 10, 2017 at 12:59 PM
Promoted
Enhancing Efficiency in your Practices: Unleashing the Power of Greenway Health’s Optimization Services
Resolve your healthcare information technology concerns by optimizing your technology, boosting workflows, improving staff productivity, and driving revenue.
MedCity >> Inbox
Get the latest industry news first when you subscribe to our newsletter.
We will never sell or share your information without your consent. See our privacy policy.Promoted
Payer’s Place: Don Antonucci
The CEO of Providence Health Plan visits the Payer’s Place and addresses the future of payment models.